Immunitybio Inc (NASDAQ:IBRX)
| 3.68 Delayed Data As of Dec 05 |  -0.04 / -1.08%Today’s Change | 1.21 Today|||52-Week Range 7.10 | -27.42% Year-to-Date |
Latest IBRX News | Press Releases
| Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now Dec 04 / Zacks.com - Paid Partner Content | ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross Nov 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 3.72 |
| Today’s open | 3.71 |
| Day’s range | 3.61 - 3.79 |
| Volume | 73,825 |
| Average volume (3 months) | 4,595,840 |
| Market cap | $2.5B |
Data as of 3:59pm ET, 12/05/2023
Growth & Valuation
| Earnings growth (last year) | -16.91% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -47.93% |
| Revenue growth (last year) | -74.30% |
| P/E ratio | NM |
| Price/Sales | 8,447.90 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ARWRArrowhead Pharmaceut... | -1.51 | -6.06% |
| AXSMAxsome Therapeutics ... | +1.19 | +1.76% |
| ---- | ||
| DNLIDenali Therapeutics ... | -0.23 | -1.23% |
Data as of 3:59pm ET, 12/05/2023
Financials
| Next reporting date | February 27, 2024 |
| EPS forecast (this quarter) | -$0.24 |
| Annual revenue (last year) | $240.0K |
| Annual profit (last year) | -$416.6M |
| Net profit margin | -173,569.58% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
